Publications by authors named "Steven D Reich"

Claim this Profile
M
Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data.
Daniela A Bota, Warren Mason, Santosh Kesari, Rajiv Magge, Benjamin Winograd, Steven D Reich

Neurooncol Adv· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.
Andrew Spencer, Simon Harrison, Jeffrey Zonder, Ashraf Badros, Jacob Laubach, Steven D Reich

Br J Haematol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors.
Geoffrey I Shapiro, Ulka N Vaishampayan, Patricia LoRusso, Jeremy Barton, Steven Hua, Steven D Reich

Invest New Drugs· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
Simon J Harrison, Paul Mainwaring, Timothy Price, Michael J Millward, Peeter Padrik, Steven D Reich

Clin Cancer Res· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
Nancy Levin, Andrew Spencer, Simon J Harrison, Dharminder Chauhan, Francis J Burrows, Steven D Reich

Br J Haematol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating imbalances of adverse events during biosimilar development.
Alicia M Vana, Amy W Freyman, Steven D Reich, Donghua Yin, Ruifeng Li

MAbs· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01).
Donghua Yin, Kerry B Barker, Ruifeng Li, Xu Meng, Steven D Reich

Br J Clin Pharmacol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.
Jianqing Lin, Marianna Zahurak, Tomasz M Beer, Charles J Ryan, George Wilding, Steven D Reich

Urol Oncol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas.
Monica M Mita, Matthew A Spear, Lorrin K Yee, Alain C Mita, Elisabeth I Heath, Steven D Reich

Clin Cancer Res· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Francis J Giles, William T Bellamy, Zeev Estrov, Susan M O'Brien, Srdan Verstovsek, Steven D Reich

Leuk Res· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.
Hope S Rugo, Roy S Herbst, Glenn Liu, John W Park, Merrill S Kies, Steven D Reich

J Clin Oncol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.
Glenn Liu, Hope S Rugo, George Wilding, Teresa M McShane, Jeffrey L Evelhoch, Steven D Reich

J Clin Oncol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial.
Peter Heald, Marilyn Mehlmauer, Ann G Martin, Constance A Crowley, Richard C Yocum, Steven D Reich

J Am Acad Dermatol· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis